Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Catalytic isoforms of AMP-activated protein kinase differentially regulate IMPDH activity and photoreceptor neuron function
Tae Jun Lee, … , Andrea Santeford, Rajendra S. Apte
Tae Jun Lee, … , Andrea Santeford, Rajendra S. Apte
Published January 16, 2024
Citation Information: JCI Insight. 2024;9(4):e173707. https://doi.org/10.1172/jci.insight.173707.
View: Text | PDF
Research Article Metabolism Ophthalmology

Catalytic isoforms of AMP-activated protein kinase differentially regulate IMPDH activity and photoreceptor neuron function

  • Text
  • PDF
Abstract

AMP-activated protein kinase (AMPK) plays a crucial role in maintaining ATP homeostasis in photoreceptor neurons. AMPK is a heterotrimeric protein consisting of α, β, and γ subunits. The independent functions of the 2 isoforms of the catalytic α subunit, PRKAA1 and PRKAA2, are uncharacterized in specialized neurons, such as photoreceptors. Here, we demonstrate in mice that rod photoreceptors lacking PRKAA2, but not PRKAA1, showed altered levels of cGMP, GTP, and ATP, suggesting isoform-specific regulation of photoreceptor metabolism. Furthermore, PRKAA2-deficient mice displayed visual functional deficits on electroretinography and photoreceptor outer segment structural abnormalities on transmission electron microscopy consistent with neuronal dysfunction, but not neurodegeneration. Phosphoproteomics identified inosine monophosphate dehydrogenase (IMPDH) as a molecular driver of PRKAA2-specific photoreceptor dysfunction, and inhibition of IMPDH improved visual function in Prkaa2 rod photoreceptor–knockout mice. These findings highlight a therapeutically targetable PRKAA2 isoform–specific function of AMPK in regulating photoreceptor metabolism and function through a potentially previously uncharacterized mechanism affecting IMPDH activity.

Authors

Tae Jun Lee, Yo Sasaki, Philip A. Ruzycki, Norimitsu Ban, Joseph B. Lin, Hung-Ting Wu, Andrea Santeford, Rajendra S. Apte

×

Figure 6

Mycophenolate mofetil treatment improves visual function deficits measured by electroretinography in Prkaa2-Rhod/-Rhod.

Options: View larger image (or click on image) Download as PowerPoint
Mycophenolate mofetil treatment improves visual function deficits measur...
(A and B) Representative electroretinography traces of Prkaa2-Rhod/-Rhod mass rod recovery. A 0 dB flash with 800 ms interstimulus time (IST) is represented. (A) A trace from Prkaa2fl/fl shows typical attenuated scotopic a and b waves in the test response indicated by the probe flash with 800 ms interstimulus time. (B) A trace from Prkaa2-Rhod/-Rhod shows abnormally large scotopic a and b waves with 800 ms IST in the test response indicated by the probe flash. (C) Quantification of scotopic A and scotopic B rod recovery (n = 7). Prkaa2-Rhod/-Rhod mice show significantly faster rod recovery compared to wild-type littermates (***P < 0.001, ****P < 0.0001 by post hoc Bonferroni’s multiple comparisons test; P < 0.0001 by 2-way ANOVA for both graphs). (D and E) Representative electroretinography traces of Prkaa2-Rhod/-Rhod mass rod recovery from eyes treated with vehicle or mycophenolate mofetil. (D) Vehicle-treated eyes demonstrate similar waveform shapes as (E) mycophenolate-treated eyes from the probe flash. (F) Quantification of scotopic a and scotopic b rod recovery (n = 5). Mycophenolate-treated eyes show significantly slower scotopic a and scotopic b rod recovery compared with vehicle-treated eyes (††P < 0.01 by post hoc Bonferroni’s multiple comparisons test; ***P < 0.001 by 2-way ANOVA). (G) Representative traces of full-field scotopic electroretinography from vehicle- and mycophenolate-treated eyes. Although the waveform shape is slightly altered, mycophenolate treatment improves scotopic a and scotopic b wave amplitudes compared with vehicle treatment. (H) Quantification of scotopic a and scotopic b wave amplitudes from full-field scotopic electroretinography (n = 5). Mycophenolate-treated eyes had significantly improved scotopic a and scotopic b wave amplitudes compared with vehicle-treated eyes (**P < 0.01, ***P < 0.001 by 2-way ANOVA). Values are mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts